` Chromatin Deregulation in Cancer
   

Click to Enlarge

Add To Cart

Chromatin Deregulation in Cancer


Subject Area(s):  Human Biology and DiseaseCancer Biology

Edited by Chris Vakoc, Cold Spring Harbor Laboratory; Steve Henikoff, Fred Hutchinson Cancer Research Center; Scott Armstrong, Sloan Kettering Institute

Due May 2017 • 350 pages (approx.), illustrated, index
Hardcover • $135 94.50 (click here to price in UK Pounds)
ISBN  978-1-621821-40-3
You save: 30%
You will receive free shipping on this item at checkout.
Free shipping offer applies to direct website purchases by individual U.S. and Canada customers only.

  •     Description    
  •     Contents    

Description

The human genome is packaged into chromatin, which is composed of numerous proteins that help control gene expression, DNA replication and repair, and genome stability. In recent years, it has become clear that the deregulation of chromatin structure plays an important role in numerous cancers.

Written and edited by experts in the field, this collection from Cold Spring Harbor Perspectives in Medicine examines the chromatin components that are commonly mutated, what is understood about the mechanisms that lead to hematological malignancies and solid tumors, and prospects for the therapeutic modulation of chromatin. The contributors describe how histone proteins, histone-modifying enzymes, chromatin remodelers, transcriptional regulatory complexes, enhancer-associated factors, and signaling proteins are dysregulated in cancer pathogenesis. In addition, the roles of DNA methylation and noncoding RNAs are covered.

The authors also discuss small molecules and other drugs that are currently under development or already used to treat cancer (e.g., HDAC inhibitors and DNA hypomethylating agents). This book is therefore essential reading for all cancer biologists, cell and molecular biologists, and pharmacologists interested in understanding cancer therapies.

Contents

(Preliminary)
MUTATIONS IN THE MACHINERY
Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer
Anne Laugesen, Jonas Westergaard Højfeldt, and Kristian Helin
NSD Proteins
Jonathan D. Licht and Jon Oyer
MLL-1 Fusion Protein
Scott A. Armstrong
Histone H3 Mutations
David Allis
MLL3/MLL4/COMPASS Family on Enhancers and in Cancer
Christie C. Sze and Ali Shilatifard
The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer
Courtney Hodges, Jacob G. Kirkland, and Gerald R. Crabtree
DNMT3a
Margaret Goodell
TET2
Ross L. Levine
Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer
Narsis Attar and Siavash K. Kurdistani
The Role of Additional Sex Combs-Like Proteins in Cancer
Jean-Baptiste Micol and Omar Abdel-Wahab
SETD2
Ian Davis
ATRX and DAXX: Mechanisms and Mutations
Michael A. Dyer, Zulekha A. Qadeer, David Valle-Garcia, and Emily Bernstein
CHDs
Alea A. Mills
Cohesin Mutations in Cancer
Magali De Koninck and Ana Losada
THERAPY
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Yixuan Li and Edward Seto
Therapy: Lysine Methyltransferases
Scott A. Armstrong and Ari Melnick
DNA Hypomethylating Agents in Cancer Therapy
Jean-Pierre Issa
BET Bromodomain Inhibitors
Christopher R. Vakoc
Histone Lysine Demethylase Inhibitors
Ashwini Jambhekar, Jamie N. Anastas, and Yang Shi
CONCEPTUAL
DNA Methylation and Cancer
Steve Baylin
Genetic and Epigenetic Crosstalk: Impacting Tumor Heterogeneity and Acquired Drug Resistance
Johnathan R. Whetstine
Mechanisms of Nucleosome Dynamics In Vivo
Steven Henikoff
Non-Histone Lysine Methylation in the Regulation of Cancer Pathways
Scott M. Carlson and Or Gozani
Long Noncoding RNA
Howard Chang
Index